Abstract 779
Background
The prognosis of patients with inoperable lower esophageal cancers remains poor with only option being concurrent chemo-radiation. Among the various agents available, there is no study done focusing on TWISTT score and QOL in southern Indian population.
Methods
This is a single-centre, two arm, retrospective analysis evaluating 75 patients with histologically confirmed inoperable adenocarcinoma esophagus lower 1/3rd who are on definitive chemoradiation. The patients were administered IV cisplatin 40 mg/m2 weekly IV (n = 38) as per institutional protocol vs Capecitabine 800 mg/m2 PO (n = 37) twice a day along with radiotherapy of 6600-7000 cGy over 35 fractions. Patients were evaluated over response evaluation criteria in solid tumors (RECIST) criteria 12 weeks after the last cycle of chemotherapy as well as for TWISTT score and QOL.
Results
The median duration of follow up was 20 months. Objective Response Rate (ORR) was observed in 84.2% of the patients with patients in the Cisplatin arm vs 86.4% in Capecitabine arm. There are no differences in the complete response (CR) and partial response (PR) rates in the two arms. The median overall survival was 20.7 months (95% CI: 18.8-, 28.7) in cisplatin arm vs 22.7 months (95% CI: 20.2-, 30.2). The median TWISTT score in Cisplatin was 246 days vs 228 days for capecitabine. The median QOL was similar in both arms.
Conclusions
Capecitabine vs Cisplatin along with concurrent radiotherapy had similar overall response rates and progression free survival with similar TWISTT score and QOL and either can be used for concurrent therapy based on physician/ patient preferences.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
A. Goutham.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
592 - Effects of novel targeted anticancer drugs on cytotoxicity, apoptosis, angiogenesis, EMT, drug resistance and autophagic mechanism
Presenter: Seyma Aydinlik
Session: Poster Display session 1
Resources:
Abstract
3235 - Delineating the mechanisms of alpha 1-3 fucosyltransferase FUT11 in ovarian cancer
Presenter: Qi Chen
Session: Poster Display session 1
Resources:
Abstract
3577 - The tyrosine kinase inhibitor Dasatinib blocks tumor growth, invasion and recurrence potential by interrupting the communication between cancer cells and their surrounding microenvironment in triple negative breast cancer
Presenter: Miriam Nuncia-Cantarero
Session: Poster Display session 1
Resources:
Abstract
4808 - NORE1A induces a feedback termination of TNF signaling by antagonizing TNFR1 through ITCH-mediated destruction complex
Presenter: Jieun Ahn
Session: Poster Display session 1
Resources:
Abstract
1294 - Hsp90 inhibitors enhance the antitumoral effect of osimertinib and overcome osimertinib resistance in non-small-cell cell lung cancer cell models
Presenter: Jordi Codony-Servat
Session: Poster Display session 1
Resources:
Abstract
1559 - Expression of IL-17RA promotes cancer stem-like properties of colorectal cancer cells by Stat3 activation
Presenter: Chih-Yung Yang
Session: Poster Display session 1
Resources:
Abstract
1615 - Adaption of Pancreatic Cancer Cells to AKT1 Inhibition Induces the Acquisition of Cancer Stem-Cell Like Phenotype Through Upregulation of Mitochondrial Functions
Presenter: Hugo Arasanz
Session: Poster Display session 1
Resources:
Abstract
4793 - Bub3 is phosphorylated by the Ataxia-Telangiectasia Mutated Kinase in mitosis and required for activation of the mitotic spindle checkpoint in Breast Cancer
Presenter: Mingming Xiao
Session: Poster Display session 1
Resources:
Abstract
1448 - The regulation of INK4 locus by long non-coding RNAs
Presenter: Yojiro Kotake
Session: Poster Display session 1
Resources:
Abstract
1858 - Vascular Endothelial Growth Factor in Colorectal Cancer Pathology, Survival and Treatment
Presenter: Liz Baker
Session: Poster Display session 1
Resources:
Abstract